Condition
IDH1-mutant Glioma
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Recruiting1
Not Yet Recruiting1
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07703436Phase 2Not Yet Recruiting
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
NCT06478212Phase 1Active Not RecruitingPrimary
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
NCT05303519Phase 3Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Showing all 3 trials